Healthy Volunteer Clinical Trial
Official title:
An Open Study to Assess the Safety and Pharmacokinetics of Fluorothyazinone Used as a Single-Dose Administration or a Treatment Course in Healthy Volunteers
The current Phase I clinical trial has been developed to assess the safety and tolerability of the Fluorothyazinone drug used as a single-dose administration and a treatment course in healthy volunteers. This dose-escalation trial will be conducted with sequential enrollment of volunteers.
Status | Completed |
Enrollment | 25 |
Est. completion date | December 15, 2017 |
Est. primary completion date | December 8, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: - - subject is a male or female between the age of 18 - 45 years; - subject provides written informed consent; - subject agrees to use effective contraceptive methods during the entire period of participation in the study (one of the following methods will be used: sexual abstinence; condoms (male or female with or without spermicidal agent); diaphragm or cervical cap with spermicidal agent; intrauterine device); in cases where subjects use hormonal contraceptives, their administration should be discontinued at least 2 months prior to the study commencement date; - body mass index (BMI) of subject: 18.5 = BMI = 30; - subject has no acute communicable diseases/recurrence of chronic communicable diseases during the participation in the study and 7 days prior to start of the therapy; - subject has no severe allergic diseases in the medical history (anaphylactic shock, Quincke's edema, polymorphic exudative eczema, serum disease); - in medical history and based on the screening results, subject has no diseases of the gastrointestinal system, liver, kidneys, cardiovascular system, CNS, locomotion system, urogenital and endocrine systems that could affect the assessment of the study results; - subject has a negative result of the blood or urine pregnancy test (for females of childbearing age) not more than 24 hours prior to receiving the first dose of the studied product; - subject has negative tests for HIV, hepatitis B and c, syphilis; - subject has a negative result of the urine test for residual narcotic drugs; - subject has a negative result of the breath alcohol test; - subject has no hematopoietic malignancies; - subject has no malignant neoplasms; - indicators of clinical biochemical analysis, complete blood count and clinical urine test at a screening visit are within the normal range of reference values* Exclusion Criteria: - - subject has participated in another clinical trial over the last 90 days; - subject has experienced symptoms of respiratory disease for the last 3 days; - subject has received treatment with steroids for the last 10 days (except products for intranasal and topical application); - subject has received immunoglobulins or other blood products over the last 3 months; - subject has received immunosuppressive and/or immunomodulating agents within 6 months prior to the start of the study; - subject has taken medications that have considerable effects on hemodynamics, liver function, etc. (barbiturates, omeprosole, cimetidine, etc.) within less than 30 days prior to the start of the study; - regular previous or current use of narcotic drugs by subject; - pregnancy or breast feeding; - GI system surgeries in subject's history within a one-year period before the subject enters the study; - subject has systolic blood pressure less than 100 mm Hg or greater than 139 mm Hg; diastolic blood pressure less than 60 mm Hg or greater than 90 mm Hg; heart rate lower than 60 beats per minute or above 90 beats per minute; - subject has exacerbation of allergic diseases or history of anaphylactic reactions or angioneurotic edema; - allergic reactions to components of the studied product and concurrent antibacterial agent; - subject has a concomitant disease which may affect the assessment of the study results: active TB form; chronic hepatic and renal diseases; considerable impairment of thyroid function and other endocrine diseases (diabetes mellitus), severe diseases of the hematopoietic system; epilepsy and other CNS disorders; myocardial infarction in previous history; myocarditis; endocarditis; ischemic heart disease; autoimmune disorders; severe chronic diseases requiring follow-up at the hospital; and, other diseases that, in opinion of the Investigator, will not allow a subject to take part in the study or may affect the study course and/or its results (e.g. assessment of the safety parameters); - blood donation (at least 450 ml of blood or plasma) by subject in less than 2 months prior to the start of the study; - subject has a history of the consumption of more than 5 units (0.25 l of pure alcohol) a week - subject smokes more than 10 cigarettes a day; - scheduled hospitalization and/or surgery during the period of participation in the study. |
Country | Name | City | State |
---|---|---|---|
Russian Federation | Federal State Budget-Funded Educational Institution for Additional Professional Education "Russian Medical Academy for Postgraduate Education" of the Ministry of Health of the Russian Federation | Moscow |
Lead Sponsor | Collaborator |
---|---|
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Center of Pharmaceutical Analytics |
Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Product safety evaluation by assessing its impact on the vital signs (systolic and diastolic blood pressure, heart rate, body temperature) and clinical laboratory test results in healthy volunteers after administration of the product | To evaluate the product safety by assessing its impact on the vital signs (systolic and diastolic blood pressure, heart rate, body temperature) and clinical laboratory test results in healthy volunteers after administration of the product | through study completion, an average of 3 month | |
Secondary | PK parameters: area under the concentration-time curve from time zero to last measurable concentration in blood sample [AUCo-t] | To assess the pharmacokinetics in healthy volunteers after the product administration as a single dose of 600 mg (10 time points: Day 1 - prior to the product administration and 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours and 12 hours after the product administration; Day 2 - 24 and 36 hours after the product administration; Day 3 - 48 hours after the product administration) To assess the pharmacokinetics in healthy volunteers after the product administration as dose 3900 mg (18 time points: Day 1 - prior to the product administration and 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours and 12 hours after the product administration; Day 2 - 24 and 36 hours after the product administration; 48 hours after the product administration; Day 4 - 71, 74, 83, 86 hours after the product administration; Day 6 - 119, 122, 131 and 134 hours after the product administration.) | 600 mg - Day 1, Day 2, Day 3; 3900 mg - Day 1, Day 2, Day 3, Day 4, Day 5, Day 6 | |
Secondary | PK parameters: area under the concentration-time curve (from time zero to infinity) [AUCo-8] | To assess the pharmacokinetics in healthy volunteers after product administration as a single dose of 600 mg (10 time points: Day 1 - prior to the product administration and 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours and 12 hours after the product administration; Day 2 - 24 and 36 hours after the product administration; Day 3 - 48 hours after the product administration) To assess the pharmacokinetics in healthy volunteers after the product administration as dose 3900 mg (18 time points: Day 1 - prior to the product administration and 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours and 12 hours after the product administration; Day 2 - 24 and 36 hours after the product administration; 48 hours after the product administration; Day 4 - 71, 74, 83, 86 hours after the product administration; Day 6 - 119, 122, 131 and 134 hours after the product administration.) | 600 mg - Day 1, Day 2, Day 3; 3900 mg - Day 1, Day 2, Day 3, Day 4, Day 5, Day 6 | |
Secondary | PK parameters: the maximum concentration [Cmax] | To assess the pharmacokinetics in healthy volunteers after product administration as a single dose of 600 mg (10 time points: Day 1 - prior to the product administration and 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours and 12 hours after the product administration; Day 2 - 24 and 36 hours after the product administration; Day 3 - 48 hours after the product administration) To assess the pharmacokinetics in healthy volunteers after the product administration as dose 3900 mg (18 time points: Day 1 - prior to the product administration and 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours and 12 hours after the product administration; Day 2 - 24 and 36 hours after the product administration; 48 hours after the product administration; Day 4 - 71, 74, 83, 86 hours after the product administration; Day 6 - 119, 122, 131 and 134 hours after the product administration.) | 600 mg - Day 1, Day 2, Day 3; 3900 mg - Day 1, Day 2, Day 3, Day 4, Day 5, Day 6 | |
Secondary | PK parameters: time to reach the maximum concentration [Tmax] | To assess the pharmacokinetics in healthy volunteers after product administration as a single dose of 600 mg (10 time points: Day 1 - prior to the product administration and 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours and 12 hours after the product administration; Day 2 - 24 and 36 hours after the product administration; Day 3 - 48 hours after the product administration) To assess the pharmacokinetics in healthy volunteers after the product administration as dose 3900 mg (18 time points: Day 1 - prior to the product administration and 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours and 12 hours after the product administration; Day 2 - 24 and 36 hours after the product administration; 48 hours after the product administration; Day 4 - 71, 74, 83, 86 hours after the product administration; Day 6 - 119, 122, 131 and 134 hours after the product administration.) | 600 mg - Day 1, Day 2, Day 3; 3900 mg - Day 1, Day 2, Day 3, Day 4, Day 5, Day 6 | |
Secondary | PK parameters: half-life [T1/2] | To assess the pharmacokinetics in healthy volunteers after product administration as a single dose of 600 mg (10 time points: Day 1 - prior to the product administration and 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours and 12 hours after the product administration; Day 2 - 24 and 36 hours after the product administration; Day 3 - 48 hours after the product administration) To assess the pharmacokinetics in healthy volunteers after the product administration as dose 3900 mg (18 time points: Day 1 - prior to the product administration and 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours and 12 hours after the product administration; Day 2 - 24 and 36 hours after the product administration; 48 hours after the product administration; Day 4 - 71, 74, 83, 86 hours after the product administration; Day 6 - 119, 122, 131 and 134 hours after the product administration.) | 600 mg - Day 1, Day 2, Day 3; 3900 mg - Day 1, Day 2, Day 3, Day 4, Day 5, Day 6 | |
Secondary | PK parameters: elimination rate constant [kel] | To assess the pharmacokinetics in healthy volunteers after product administration as a single dose of 600 mg (10 time points: Day 1 - prior to the product administration and 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours and 12 hours after the product administration; Day 2 - 24 and 36 hours after the product administration; Day 3 - 48 hours after the product administration) To assess the pharmacokinetics in healthy volunteers after the product administration as dose 3900 mg (18 time points: Day 1 - prior to the product administration and 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours and 12 hours after the product administration; Day 2 - 24 and 36 hours after the product administration; 48 hours after the product administration; Day 4 - 71, 74, 83, 86 hours after the product administration; Day 6 - 119, 122, 131 and 134 hours after the product administration.) | 600 mg - Day 1, Day 2, Day 3; 3900 mg - Day 1, Day 2, Day 3, Day 4, Day 5, Day 6 | |
Secondary | PK parameters: volume of distribution [Vd] | To assess the pharmacokinetics in healthy volunteers after product administration as a single dose of 600 mg (10 time points: Day 1 - prior to the product administration and 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours and 12 hours after the product administratio; Day 2 - 24 and 36 hours after the product administration; Day 3 - 48 hours after the product administration) To assess the pharmacokinetics in healthy volunteers after the product administration as dose 3900 mg (18 time points: Day 1 - prior to the product administration and 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours and 12 hours after the product administration; Day 2 - 24 and 36 hours after the product administration; 48 hours after the product administration; Day 4 - 71, 74, 83, 86 hours after the product administration; Day 6 - 119, 122, 131 and 134 hours after the product administration.) | 600 mg - Day 1, Day 2, Day 3; 3900 mg - Day 1, Day 2, Day 3, Day 4,Day 5, Day 6 | |
Secondary | PK parameters: relative rate of absorption [Cmax/AUC] | To assess the pharmacokinetics in healthy volunteers after product administration as a single dose of 600 mg (10 time points: Day 1 - prior to the product administration and 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours and 12 hours after the product administration; Day 2 - 24 and 36 hours after the product administration; Day 3 - 48 hours after the product administration) To assess the pharmacokinetics in healthy volunteers after the product administration as dose 3900 mg (18 time points: Day 1 - prior to the product administration and 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours and 12 hours after the product administration; Day 2 - 24 and 36 hours after the product administration; 48 hours after the product administration; Day 4 - 71, 74, 83, 86 hours after the product administration; Day 6 - 119, 122, 131 and 134 hours after the product administration.) | 600 mg - Day 1, Day 2, Day 3; 3900 mg - Day 1, Day 2, Day 3, Day 4, Day 5, Day 6 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06326723 -
Investigate the PK, Safety, and Tolerability After Single and Multiple Dose Daridorexant in Chinese Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT00001367 -
Diagnosis and History Study of Patients With Different Neurological Conditions
|
||
Completed |
NCT02699710 -
Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics (PK) of GDC-0853 and the Effect of GDC-0853 on the PK of Methotrexate in Healthy Subjects
|
Phase 1 | |
Completed |
NCT02231892 -
Repetitive Transcranial Magnetic Stimulation Equipment Testing and Pilot Study
|
N/A | |
Not yet recruiting |
NCT06441916 -
Bioequivalence Study of Dabigatran Etexilate Capsules 150 mg in Healthy Thai Volunteers Under Fasting Conditions
|
Phase 1 | |
Completed |
NCT03771586 -
A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT06337422 -
Bioequivalence Study of Generic Celecoxib 200 mg Capsules
|
Phase 1 | |
Completed |
NCT03302182 -
Bioequivalence Study of Ritonavir Versus NORVIR in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT05049343 -
Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants
|
Phase 1 | |
Recruiting |
NCT01629108 -
Normal Values in Hearing and Balance Testing
|
||
Completed |
NCT02947854 -
Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant
|
Phase 1 | |
Completed |
NCT02534870 -
Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT02224053 -
Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01711762 -
A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT01697436 -
A Bioequivalence Study of an Oral Solution of Copegus (Ribavirin) Compared to Copegus Tablets
|
Phase 1 | |
Completed |
NCT01676584 -
A Study of Single Dose RO6811135 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01684891 -
A 28-Day Pharmacokinetics Study of RG1662 in Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT02547259 -
Influence of Emotion in a Test Run Forgetfulness
|
N/A | |
Completed |
NCT01433575 -
A Pharmacokinetic Study of RO4917838 in Healthy Chinese Volunteers
|
Phase 1 | |
Completed |
NCT01591850 -
A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers
|
Phase 1 |